November 1, 2007 - The American College of Obstetricians and Gynecologists (ACOG) announced new recommendations emphasizing colonoscopy as the preferred method for colorectal cancer screening for both average-risk and high-risk women.

ACOG changed its colorectal cancer screening recommendations because colonoscopy allows for direct visualization of the entire colon surface, and it allows for removal of any precancerous polyps at the same time. Additionally, colonoscopy allows access to right-sided lesions-the main type of advanced colorectal cancer occurring in women-which are more likely to be missed by other screening methods. Previously, ACOG recommended that all women age 50 and older be screened for colorectal cancer by one of several methods, with no single method being preferred over another.

"Our message today is that colonoscopy is the gold standard when it comes to colorectal cancer screening. While we want ob-gyns to encourage this method, they should still discuss the advantages and limitations of the other screening options with their patients," said Carol L. Brown, M.D., immediate past vice chair of ACOG's Committee on Gynecologic Practice, which developed the recommendations. "The bottom line is we want women to get tested by whichever method they are most likely to accept and follow through with."

According to the Committee Opinion, ACOG does not recommend fecal DNA testing or computed tomography colonography (also known as "virtual colonoscopy") for screening outside the research setting, pending further data on their effectiveness.

For more information: www.acog.com


Related Content

News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Feature | Cardio-oncology | Dave Fornell

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat ...

Time May 13, 2016
arrow
News | Oncology Related Products

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy ...

Time May 06, 2016
arrow
Subscribe Now